Nhi Nguyen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Nhi Nguyen has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Kevin Lin
The University of Texas MD Anderson Cancer Center
2 shared publications Adenike Olabode
Memorial Hermann The Woodlands Hospital
1 shared publication- Ahmed Zaki
Memorial Hermann Greater Heights
1 shared publication Christy P. Su
Houston Methodist West Hospital
1 shared publication- Cora Alperin
Section of Infectious Diseases, Department of Medicine, Baylor College of Medicine (BCM) , Houston, Texas
1 shared publication - Eva H. Clark
Section of Infectious Diseases, Department of Medicine and Division of Tropical Medicine, Department of Pediatrics, BCM , Houston, Texas
1 shared publication
Latest Publications
- 16 September 2026
- Published by SAGE Publications in Journal of Pharmacy Practice
Significant Publications on Infectious Diseases Pharmacotherapy in 2025
This review provides summarization of the most significant infectious diseases (ID) pharmacotherapy articles published in peer-reviewed literature in 2025. Members of the Houston Infectious Diseases Network (HIDN) nominated notable articles providing significant contributions to ID pharmacotherapy in 2025. Article nominations included those pertaining to general ID and human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) pharmacotherapy. To aid selection of the most notable articles of 2025, a survey was created and distributed to members of the Society of Infectious Diseases Pharmacists (SIDP). A total of 32 articles were nominated by HIDN/SIDP members, 26 articles related to general ID pharmacotherapy and 6 articles focusing on HIV/AIDS. Of the 212 SIDP members who participated in the survey, there were 101 recorded votes for the top 10 general ID pharmacotherapy articles and 40 votes recorded for the top HIV/AIDS article. The most notable publications are summarized. Ongoing research continues to discover findings that enhance antimicrobial stewardship and inform best practices in infectious diseases. From over 2000 articles published on PubMed using the keywords “infectious diseases,” “HIV,” “pharmacotherapy,” and “anti-infective,” this review highlights and summarizes the most influential ID publications with aims to update clinicians on potentially practice-changing ID pharmacotherapy publications from 2025.
- 16 September 2026
- Published by SAGE Publications in Journal of Pharmacy Practice
Significant Publications on Infectious Diseases Pharmacotherapy in 2025
This review provides summarization of the most significant infectious diseases (ID) pharmacotherapy articles published in peer-reviewed literature in 2025. Members of the Houston Infectious Diseases Network (HIDN) nominated notable articles providing significant contributions to ID pharmacotherapy in 2025. Article nominations included those pertaining to general ID and human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) pharmacotherapy. To aid selection of the most notable articles of 2025, a survey was created and distributed to members of the Society of Infectious Diseases Pharmacists (SIDP). A total of 32 articles were nominated by HIDN/SIDP members, 26 articles related to general ID pharmacotherapy and 6 articles focusing on HIV/AIDS. Of the 212 SIDP members who participated in the survey, there were 101 recorded votes for the top 10 general ID pharmacotherapy articles and 40 votes recorded for the top HIV/AIDS article. The most notable publications are summarized. Ongoing research continues to discover findings that enhance antimicrobial stewardship and inform best practices in infectious diseases. From over 2000 articles published on PubMed using the keywords “infectious diseases,” “HIV,” “pharmacotherapy,” and “anti-infective,” this review highlights and summarizes the most influential ID publications with aims to update clinicians on potentially practice-changing ID pharmacotherapy publications from 2025.
- Open Access
- 26 December 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (1)
Priced Out of Treatment: The Exorbitant Cost of Antiparasitic Drugs in the United States
Parasitic infections are often perceived as diseases of low-resource countries, yet they impose a significant and overlooked burden in the United States—especially among immigrants, low-income individuals, and other marginalized populations. This perspectives article examines the case of Mr. X, a landscaper in Houston diagnosed with neurocysticercosis, who faced unaffordable drug costs despite the availability of effective, off-patent treatments. Through his story, we explore the broader issue of pricing for commonly and not-so-commonly prescribed antiparasitic medications, highlighting the role of systemic market failures, regulatory hurdles, and restrictive assistance programs in limiting access to care. The consequences of incomplete treatment include long-term disability, public health risks, and deepened health disparities. We propose policy solutions, including reforms to the Orphan Drug Act, expansion of Medicare negotiation powers, and investment in public-interest drug production, to improve affordability and ensure equitable access to essential antiparasitic drugs.
- 26 December 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (1)
Open AccessPriced Out of Treatment: The Exorbitant Cost of Antiparasitic Drugs in the United States
Parasitic infections are often perceived as diseases of low-resource countries, yet they impose a significant and overlooked burden in the United States—especially among immigrants, low-income individuals, and other marginalized populations. This perspectives article examines the case of Mr. X, a landscaper in Houston diagnosed with neurocysticercosis, who faced unaffordable drug costs despite the availability of effective, off-patent treatments. Through his story, we explore the broader issue of pricing for commonly and not-so-commonly prescribed antiparasitic medications, highlighting the role of systemic market failures, regulatory hurdles, and restrictive assistance programs in limiting access to care. The consequences of incomplete treatment include long-term disability, public health risks, and deepened health disparities. We propose policy solutions, including reforms to the Orphan Drug Act, expansion of Medicare negotiation powers, and investment in public-interest drug production, to improve affordability and ensure equitable access to essential antiparasitic drugs.
- Open Access
- 11 December 2025
- Published by SAGE Publications in Journal of Pharmacy Practice
- Vol. 39 (4) , 257-270
Significant Publications on Infectious Diseases Pharmacotherapy in 2024
Purpose: To provide a summarization of the most significant infectious diseases (ID) pharmacotherapy articles published in peer-reviewed literature in 2024. Summary: Members of the Houston Infectious Diseases Network (HIDN) nominated notable articles providing significant contributions to ID pharmacotherapy in 2024. Article nominations included those pertaining to general ID and human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) pharmacotherapy in 2024. To aid selection of the most significant articles in 2024, a survey was created and distributed to members of the Society of Infectious Diseases Pharmacists (SIDP). Out of the 21 total articles nominated by HIDN/SIDP members, 19 pertained to general ID pharmacotherapy, and 2 had pertained to HIV/AIDS pharmacotherapy. Of the SIDP members who participated in the survey, 185 voted for the top 10 general ID pharmacotherapy articles and 46 votes were recorded for the top HIV/AIDS article. The most notable publications are summarized. Conclusion: This review provides a summary of the most recently published ID literature with aims to update clinicians on the current potential practice changing ID pharmacotherapy publications from 2024.
- 11 December 2025
- Published by SAGE Publications in Journal of Pharmacy Practice
- Vol. 39 (4) , 257-270
Open AccessSignificant Publications on Infectious Diseases Pharmacotherapy in 2024
Purpose: To provide a summarization of the most significant infectious diseases (ID) pharmacotherapy articles published in peer-reviewed literature in 2024. Summary: Members of the Houston Infectious Diseases Network (HIDN) nominated notable articles providing significant contributions to ID pharmacotherapy in 2024. Article nominations included those pertaining to general ID and human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) pharmacotherapy in 2024. To aid selection of the most significant articles in 2024, a survey was created and distributed to members of the Society of Infectious Diseases Pharmacists (SIDP). Out of the 21 total articles nominated by HIDN/SIDP members, 19 pertained to general ID pharmacotherapy, and 2 had pertained to HIV/AIDS pharmacotherapy. Of the SIDP members who participated in the survey, 185 voted for the top 10 general ID pharmacotherapy articles and 46 votes were recorded for the top HIV/AIDS article. The most notable publications are summarized. Conclusion: This review provides a summary of the most recently published ID literature with aims to update clinicians on the current potential practice changing ID pharmacotherapy publications from 2024.